Valuation: Actinium Pharmaceuticals, Inc.

Market Cap 2.63Cr 2.28Cr 2.12Cr 1.95Cr 3.68Cr 250.66Cr 3.74Cr 25Cr 9.83Cr 124.79Cr 9.86Cr 9.64Cr 418.44Cr P/E 2026 *
-0.99x
P/E 2027 * -1.49x
Enterprise Value 2.63Cr 2.28Cr 2.12Cr 1.95Cr 3.68Cr 250.66Cr 3.74Cr 25Cr 9.83Cr 124.79Cr 9.86Cr 9.64Cr 418.44Cr EV / Sales 2026 *
-
EV / Sales 2027 * 2.03x
Free-Float
97.65%
Yield 2026 *
-
Yield 2027 * -
03/06 Actinium Pharmaceuticals Presents New Data on Atnm-400 Demonstrating Potent Activity in Prostate Cancer Models Resistant to All Three Approved Androgen Receptor Inhibitors CI
01/06 Actinium Pharmaceuticals, Inc. Appoints Steffen Heeger as Chief Medical Officer CI
01/06 Actinium Pharmaceuticals Presents New Radiochemistry Data Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates CI
30/05 Actinium Pharmaceuticals - receives two Canadian patent allowances for Actimab-A and Iomab-Act programs RE
30/05 Actinium Pharmaceuticals Receives Patent Allowances for Actimab-A and Iomab-Act Programs in Canada CI
09/05 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
06/05 Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of Atnm-400 Across Lung and Prostate Cancer and Radioconjugate Optimization CI
22/04 Actinium Pharmaceuticals, Inc. Highlights Transcriptional Reprogramming As Key Mechanism Underpinning Mutation-Agnostic Activity Of Actimab-A In AML CI
22/04 Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models At the 2026 American Association of Cancer Research Annual Meeting CI
07/04 Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for Atnm-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in Aml CI
31/03 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
17/02 CNS Pharmaceuticals, Inc. Announces Chief Financial Officer Changes, Effective March 2, 2026 CI
14/02 Actinium Pharmaceuticals, Inc. Announces Executive Changes, Effective as of February 27, 2026 CI
1 day-0.01%
1 week-2.69%
1 month-14.60%
3 months-24.60%
6 months-27.85%
Current year-38.46%
1 week 0.81
Extreme 0.8068
0.88
1 month 0.81
Extreme 0.8068
1.05
Current year 0.81
Extreme 0.8068
1.53
1 year 0.81
Extreme 0.8068
1.81
3 years 0.81
Extreme 0.8068
10.24
5 years 0.81
Extreme 0.8068
15.12
10 years 0.81
Extreme 0.8068
64.5
Manager TitleAgeSince
Chief Executive Officer 62 09/06/2017
Chief Tech/Sci/R&D Officer - 01/06/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 71 01/01/2008
Chairman 62 01/10/2013
Director/Board Member 68 08/11/2013
Date Insider Type Main position Quantity % Market Cap.
18/08/25 Tax

Chief Executive Officer

1,20,900 0.3876%
31/03/25 Issuer sale

Chief Financial Officer

7,06,588 2.2650%
31/03/25 Issuer sale

Chief Executive Officer

23,85,976 7.6484%
Change 5-day change 1-year change 3-year change Capi.($)
-0.01%-2.69%-48.66%-88.25% 2.63Cr
+2.35%+2.74%+33.41%+79.20% 5.65TCr
-0.21%-7.38%+25.34%+63.02% 5.36TCr
-2.44%+1.40%-15.74%-16.80% 2.29TCr
-2.85%-7.78%-8.09%+346.36% 2.14TCr
+2.49%-0.92%+20.31%-12.15% 2.03TCr
+0.79%-1.06%+29.29%-33.32% 1.76TCr
+0.58%-5.88%+16.30%+540.37% 1.47TCr
-5.25%-4.23%+46.41%+169.05% 1.33TCr
+3.41%-6.61%+163.08%+280.43% 1.35TCr
Average -0.11%-3.68%+26.16%+132.79% 2.34TCr
Weighted average by Cap. +0.23%-2.96%+28.66%+119.96%

Financials

2026 *2027 *
Net sales - 1.29Cr 1.12Cr 1.05Cr 96.03L 1.81Cr 123.4Cr 1.84Cr 12Cr 4.84Cr 61Cr 4.85Cr 4.75Cr 206Cr
Net income -2.85Cr -2.48Cr -2.31Cr -2.12Cr -4Cr -272.06Cr -4.06Cr -27Cr -11Cr -135.44Cr -11Cr -10Cr -454.17Cr -2.33Cr -2.02Cr -1.88Cr -1.73Cr -3.26Cr -222.12Cr -3.31Cr -22Cr -8.71Cr -110.58Cr -8.74Cr -8.55Cr -370.79Cr
Net Debt - -
Logo Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. It operates a pipeline of both early and later stage development programs with two novel solid tumor product candidates, ATNM-400 and Actimab-A, with pan-tumor potential; Actimab-A, which is also being developed as a therapeutic backbone for acute myeloid leukemia and myelodysplastic syndrome in partnership with the National Cancer Institute (NCI), and two targeted conditioning agents, Iomab-B for bone marrow transplant and Iomab-ACT for cell & gene therapies. Its solid tumor asset, ATNM-400, targets a novel antigen distinct from PSMA, with demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Its hematology franchise includes Actimab-A, Iomab-B and Iomab-ACT, which are CD45-targeting conditioning agents.
Employees
25
Date Price Change Volume
31/26/31 $0.8369 -0.01% 35,412
30/26/30 $0.8370 +0.01% 26,316
29/26/29 $0.8369 -3.42% 80,795
28/26/28 $0.8665 +1.42% 72,398
27/26/27 $0.8544 -0.65% 1,23,733
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.8369USD
Average target price
5.000USD
Spread / Average Target
+497.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATNM Stock